Neoplasm News and Research

RSS

Neoplasm is an abnormal mass of tissue as a result of neoplasia.

Elsevier launches new open access journal dedicated to urology

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new open access journal: Urology Case Reports.

25 Nov 2013

Patrys gets second US patent for anti-cancer product PAT-LM1

Patrys Limited, a clinical stage biotechnology company is pleased to advise that it has been granted a second US patent for lead anti-cancer product PAT-LM1.

8 Nov 2013

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia.

24 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Proton radiotherapy proves to be cost-effective in treating pediatric brain tumors

Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that mainly affect children, when compared to standard photon radiation therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

Bone tumor identified in the rib of 120,000-year-old Neandertal

The first-known definitive case of a benign bone tumor has been discovered in the rib of a young Neandertal who lived about 120,000 years ago in what is now present-day Croatia.

10 Jun 2013

Boston Scientific presents data on breakthrough products at Digestive Disease Week 2013

Boston Scientific Corporation is scheduled to participate in Digestive Disease Week 2013, May 18-21 in Orlando, Fla.

20 May 2013

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.

10 Apr 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

Growth factor aids mandible reconstruction

Surgeons have used recombinant human bone morphogenetic protein-2 to successfully restore mandibulectomy defects with few adverse effects.

12 Feb 2013

Colorectal cancer screening: an interview with Dr Donato F. Altomare

Colorectal cancer is a malignant neoplasm affecting the large bowel and the rectum mainly after the 5th decade of life and representing the second cause of death for cancer in western countries (the third in women). In about 15-20% of patients there is an inherited predisposition.

29 Jan 2013

Study reports on development and testing of Hematuria Risk Index to predict cancer risk

Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk.

10 Jan 2013

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Cell Therapeutics, Inc. (CTI) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.

9 Jan 2013

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

H. pylori colonic neoplasm link confirmed

Helicobacter pylori gastritis is significantly associated with colonic neoplasms, show the results of one of the largest studies of the association to date.

6 Dec 2012

Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.

8 Nov 2012

Patients with chronic constipation at increased risk of colorectal cancer, benign neoplasms

Patients with chronic constipation may be at increased risk of developing colorectal cancer and benign neoplasms, according to study findings unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

22 Oct 2012